Breaking News

Astellas, LabCentral Name Thymmune and M13 Innovator Prize Winners

Companies will have access to a year of life-science incubator in Cambridge and Astellas expertise to further their research.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Astellas Venture Management LLC, a venture capital subsidiary of Astellas Pharma Inc., and LabCentral, a launchpad for early-stage life-sciences startups, announced Thymmune Therapeutics and M13 Therapeutics as the winners of the Astellas-sponsored “Future Innovator Prize” at LabCentral. The award offers entrepreneurial scientists or emerging biotechnology startups one-year access to LabCentral’s state-of-the-art lab facility in Cambridge, MA, as well as access to Astellas&#821...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters